These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31951875)

  • 1. Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
    Håkansson I; Ernerudh J; Vrethem M; Dahle C; Ekdahl KN
    J Neuroimmunol; 2020 Mar; 340():577147. PubMed ID: 31951875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
    Oechtering J; Stein K; Schaedelin SA; Maceski AM; Orleth A; Meier S; Willemse E; Qureshi F; Heijnen I; Regeniter A; Derfuss T; Benkert P; D'Souza M; Limberg M; Fischer-Barnicol B; Achtnichts L; Mueller S; Salmen A; Lalive PH; Bridel C; Pot C; Du Pasquier RA; Gobbi C; Wiendl H; Granziera C; Kappos L; Trendelenburg M; Leppert D; Lunemann JD; Kuhle J;
    Neurol Neuroimmunol Neuroinflamm; 2024 Mar; 11(2):e200212. PubMed ID: 38354323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
    Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis.
    Håkansson I; Gouveia-Figueira S; Ernerudh J; Vrethem M; Ghafouri N; Ghafouri B; Nording M
    Prostaglandins Other Lipid Mediat; 2018 Sep; 138():41-47. PubMed ID: 30118859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function.
    Lindblom RP; Aeinehband S; Ström M; Al Nimer F; Sandholm K; Khademi M; Nilsson B; Piehl F; Ekdahl KN
    Clin Immunol; 2016 May; 166-167():89-95. PubMed ID: 27085202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
    Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission.
    Veszeli N; Füst G; Csuka D; Trauninger A; Bors L; Rozsa C; Nagy Z; Jobbágy Z; Eizler K; Prohászka Z; Varga L; Illes Z
    Mol Immunol; 2014 Feb; 57(2):200-9. PubMed ID: 24172223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
    Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis.
    Blauth K; Zhang X; Chopra M; Rogan S; Markovic-Plese S
    Clin Immunol; 2015 Apr; 157(2):121-32. PubMed ID: 25596452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Sfagos C
    J Neuroendocrinol; 2010 Jun; 22(6):503-8. PubMed ID: 20236233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
    Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
    J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
    Fissolo N; Cervera-Carles L; Villar Guimerans LM; Lleó A; Clarimón J; Drulovic J; Dujmovic I; Voortman M; Khalil M; Gil E; Navarro L; Álvarez-Cermeño JC; Montalban X; Comabella M
    Mult Scler; 2019 Oct; 25(11):1535-1538. PubMed ID: 29985092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation in patients with neuromyelitis optica.
    Nytrova P; Potlukova E; Kemlink D; Woodhall M; Horakova D; Waters P; Havrdova E; Zivorova D; Vincent A; Trendelenburg M
    J Neuroimmunol; 2014 Sep; 274(1-2):185-91. PubMed ID: 25109258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
    Orbach R; Gurevich M; Achiron A
    Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.